System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Konstantinos Kostikas is an expert in Pulmonology at University Hospital of Ioannina (Greece). As of October 2026, ScienceLeadR ranks Konstantinos Kostikas in the top 1% of experts worldwide for Respiratory Aspiration, Asthma and Respiration Disorders. Konstantinos Kostikas has authored 490 publications, the most recent in 2026, and is an investigator in 42 clinical trials, 17 of them ongoing. SLR score: 2,270 (community average: 125). How the SLR is computed.

LeadR Profile

Konstantinos Kostikas University Hospital of Ioannina Greece
2 270 ScienceLeadR Reputation 2270

Unlock

Register Login
Network Map

Pulmonology

Subspecialties: Immunology - Public Health - Critical Care

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2005 - 2026
Source: PubMed

University of Ioannina

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 490

Citations

Citations: 9 976 1st author: 57 Last author: 108 Unique author: 5

Main journals

05.01 - Airway pharmacology and treatment 33
05.02 - Monitoring airway disease 31
Eur Respir J 20
Respir Med 20
Chest 19

Best Journals

N Engl J Med 7
Am J Respir Crit Care Med 1
Eur Respir J 1

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Beyond the Average Treatment Effect: Toward Precision Immunosuppression in Fibrotic Interstitial Lung Disease.
PMID 42788658 — lung, critical care, therapeutics, lung diseases, immunosuppression therapy, lung diseases, interstitial		Am J Respir Crit Care Med20260
Evaluating Satisfaction and Quality of Life with Elpenhaler: A Pooled Analysis of Real-Life Studies.
PMID 42775283 — quality of life, pulmonary disease, chronic obstructive, dry powder inhalers, therapeutics, asthma, education, smoking, patient satisfaction		Pragmat Obs Res20260
Global, regional, and national prevalence of second-hand smoke and attributable disease burden in 204 countries and territories, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023.
PMID 42705247 — public health, global burden of disease, smoke, prevalence, risk factors, cost of illness, child		Lancet Public Health20260
Association of Easier Biologic Access with Remission and Other Clinical Outcomes in Severe Asthma: A Global Real-World Study.
PMID 42638984 — therapeutics, asthma		J Asthma Allergy20260
Myeloma Elderly Prognostic Score (MEPS): A Proposed Prognostic Score Integrating Age, Renal Function, Performance Status, and Ultra-High-Risk Cytogenetics.
PMID 42635069 — hematology, aged, multiple myeloma, cytogenetics, prognosis		Am J Hematol20260

Clinical Studies 42

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 2

By phase:

Phase 3 21
Phase 2 10
N/A 5
Phase 4 5
Phase 2/Phase 3 1

By status:

Completed 22
Recruiting 8
Active not recruiting 7
Terminated 3
Not yet recruiting 2

By type:

Interventional 39
Observational 3

By Monocentric/Multicentric:

monocentric 7
multicentric2to4 2
multicentric5to9 0
multicentricup10 33

Main Topics

Ongoing Clinical Trials

17 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Study of Intravenous ABBV 142 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Idiopathic Pulmonary Fibrosis
2024-518013-25-00 — idiopathic pulmonary fibrosis, fibrosis, drug-related side effects and adverse reactions, pulmonary fibrosis, therapeutics		Phase 2Not yet recruiting2026
A Study to Evaluate the Efficacy Safety and Tolerability of BMS 986278 in Participants with Idiopathic Pulmonary Fibrosis
2023-503697-21-01 — idiopathic pulmonary fibrosis, safety, fibrosis, pulmonary fibrosis, vital capacity		Phase 3Active not recruiting2024
Clairleaf TM A study to test long term treatment with BI 1291583 in people with bronchiectasis who took part in a previous study with this medicine
2023-503290-38-00 — safety, therapeutics, bronchiectasis		Phase 2Active not recruiting2023
A Study to Evaluate the Efficacy Safety and Tolerability of BMS 986278 in Participants with Progressive Pulmonary Fibrosis
2023-503699-25-00 — safety, fibrosis, pulmonary fibrosis, vital capacity		Phase 3Active not recruiting2024
A Study Evaluating the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
2023-507407-59-00 — multiple chronic conditions, pulmonary disease, chronic obstructive, fumarates, metered dose inhalers, formoterol fumarate, therapeutics, lung diseases, lung diseases, obstructive, budesonide		Phase 3Recruiting2024

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS